跳转至内容
Merck
CN

32144

Supelco

Clinafloxacin

VETRANAL®, analytical standard

别名:

7-(3-Amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydroxy-4-oxo-3-quinolinecarboxylic acid

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C17H17ClFN3O3
化学文摘社编号:
分子量:
365.79
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

analytical standard

质量水平

产品线

VETRANAL®

技术

HPLC: suitable
gas chromatography (GC): suitable

应用

forensics and toxicology
veterinary

包装形式

neat

储存温度

2-8°C

SMILES字符串

NC1CCN(C1)c2c(F)cc3C(=O)C(=CN(C4CC4)c3c2Cl)C(O)=O

InChI

1S/C17H17ClFN3O3/c18-13-14-10(5-12(19)15(13)21-4-3-8(20)6-21)16(23)11(17(24)25)7-22(14)9-1-2-9/h5,7-9H,1-4,6,20H2,(H,24,25)

InChI key

QGPKADBNRMWEQR-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

Clinafloxacin is a fluoroquinolone antibiotic with a broad range of bactericidal activity, used in the treatment of gynaecologic and urinary infections. It inhibits bacterial DNA gyrase enzyme which is responsible for synthesis, replication, repair and transcription.

应用

Clinafloxacin may be used as a reference standard for the determination of clinafloxacin in urine samples of rat and human by capillary zone electrophoresis.
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

法律信息

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

象形图

Health hazard

警示用语:

Warning

危险声明

预防措施声明

危险分类

Repr. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Rapid HPLC assay of clinafloxacin, fleroxacin, levofloxacin, sparfloxacin and tosufloxacin.
Lyon DJ, et al.
The Journal of Antimicrobial Chemotherapy, 34(3), 446-448 (1994)
E J Goldstein
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 23 Suppl 1, S25-S30 (1996-12-01)
The currently available fluoroquinolones have modest activity against anaerobes. Newer fluoroquinolones with increased in vitro activity against anaerobes are under development and include levofloxacin, clinafloxacin, sparfloxacin, trovafloxacin, grepafloxacin, and DU-6859a. Side effects of the quinolones have varied according to the
A Domenech et al.
Microbial drug resistance (Larchmont, N.Y.), 9 Suppl 1, S53-S59 (2003-11-25)
The increasing incidence of ciprofloxacin resistance in Streptococcus pneumoniae may limit the efficacy of the new quinolones in difficult-to-treat infections such as meningitis. The aim of the present study was to determine the efficacy of clinafloxacin alone and in combination
Yan Wang et al.
Bioorganic & medicinal chemistry letters, 22(17), 5363-5366 (2012-08-14)
A series of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents were synthesized for the first time and screened for their antimicrobial efficacy against four Gram-positive bacteria, four Gram-negative bacteria and two fungi by two fold
J M Sierra et al.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 11(9), 750-758 (2005-08-18)
Two quinolone-susceptible Staphylococcus aureus and five quinolone-susceptible Streptococcus pneumoniae isolates were used to obtain in-vitro quinolone-resistant mutants in a multistep resistance selection process. The fluoroquinolones used were ciprofloxacin, moxifloxacin, levofloxacin, gemifloxacin, trovafloxacin and clinafloxacin. The mutagenicity of these quinolones was

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持